top of page
LOGO NATIONAL RESEARCH CENTERS BLANCO.png
social-distancing-and-self-isolation-in-quarantine-2023-11-27-04-54-54-utc_edited_edited_e

RSV 
Vaccine Respiratory Syncytial Virus

Welcome to D&H National Research Centers, where we invite you to be a part of  groundbreaking advancements in the quest to combat Respiratory Syncytial Virus (RSV). Join the cutting-edge research that brings hope and promise to millions around the globe and get up $300 Compensation.

father-and-daughter-2-3-wading-in-sea-2023-11-27-05-25-05-utc_edited.jpg

Respiratory Syncytial Virus (RSV) is a common respiratory virus that can affect individuals of all ages. The virus primarily causes infections of the respiratory tract, leading to symptoms similar to the common cold or flu. In healthy  children, RSV infections often result in mild, cold-like symptoms such as cough, congestion, runny nose, and fever. However, in infants, especially those with weakened immune systems or pre-existing health conditions, RSV infections can lead to more severe complications, including bronchiolitis (inflammation of the small airways in the lungs) and pneumonia.

Are you concerned about Respiratory Syncytial Virus? If so, you may be interested in participating in our clinical trial.  At D&H National Research Centers we are conducting research on a Vaccine for RSV that could potentially improve the quality of life and provide hope for a brighter future.

portrait-of-cheerful-mother-with-infant-baby-on-ha-2023-11-27-04-54-40-utc_edited.jpg

Our trial is designed to:

  • Scientific Excellence: Our team comprises leading experts in virology, immunology, and vaccine development. We leverage the latest technologies and methodologies to push the boundaries of what's possible.

  • Collaborative Partnerships: We believe in the power of collaboration. By partnering with top-tier research institutions, pharmaceutical companies, and health organizations, we amplify our impact and accelerate the pace of discovery.

  • Focus on Safety: The safety of our vaccines is paramount. Our rigorous testing protocols adhere to the highest industry standards, ensuring that the vaccines we develop are not only effective but also safe for widespread use.

  • Compensation: As a token of appreciation for your participation, you may be eligible for compensation for your time and travel expenses up $100.

D&H National Research Centers is currently conducting a study on Respiratory Syncytial Virus Vaccine (RSV). As a prominent leader in clinical research in Florida, we are committed to advancing medical knowledge and patient care.

Inclusion Criteria:

 

If you want to participate in this study, you must meet the following criteria:

  • Male and female aged 6 months to < 22 months on the day of inclusion.

  • Born at full term of pregnancy (≥ 37 weeks)

  • Participants who are healthy as determined by medical evaluation including medical
    history.

  • Participant’s parent(s)/LAR(s) has to provide written informed consent for participation in this study. 

Exclusion Criteria:

 

You are not eligible for participation in this study if:

 

  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy,

  • Chronic hepatitis or suspected active hepatitis.

  • History of allergic or anaphylactic reactions following a vaccination that required medical intervention.

  • History of medically diagnosed wheezing

BABY VACCINE
the-best-gift-of-life-2023-11-27-05-03-52-utc_edited.jpg

D&H National Research Centers is a leading medical trial center located in Florida. 

If you are interested in joining our Vaccine Respiratory Syncytial Virus (RSV) medical trial or have questions about the study, please don't hesitate to reach out to us. We are here to provide you with all the information and support you need, please fill the form or contact us by phone: (786) 375-6210

Join the study

bottom of page